Clinical Trial Detail

NCT ID NCT02949284
Title Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications

prostate adenocarcinoma

Therapies

Apalutamide

Abiraterone + Apalutamide + Prednisone

Age Groups: adult child senior

No variant requirements are available.